Orion and Hospira have signed a license agreement to continue the collaboration with Precedex®
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 21 OCTOBER 2013 at 8:10 p.m. EEST
Orion Corporation and Hospira, Inc. have extended their licensing agreement
concerning the sedative agent Precedex® in the markets outside the Europe. Orion
and Hospira (originally Abbott) have collaborated since 1994 on Precedex®.
Precedex® is a drug with an active ingredient dexmedetomidine originated by
Orion. The distributor for the product outside Europe is a US-company Hospira,
Inc. under Orion's license.
Dr. Liisa Hurme, Senior Vice President of Orion's Proprietary Products division,
commented the agreement:
"We are very pleased that the long-lasting co-operation will continue".
Precedex®
Dexmedetomidine is a sedative agent originated by Orion's own pharmaceutical
R&D. It is a relatively selective alpha2-agonist which acts on the central
nervous system to produce sedation. Dexmedetomidine is available with the brand
name Precedex® in more than 30 countries outside Europe, including the USA
(since 2000) and Japan (since 2004). With the brand name dexdor® dexmedetomidine
is marketed in the EU area mainly by Orion's own sales organisation (since
2012).
About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion
technologies. Through its products, Hospira helps improve the safety, cost and
productivity of patient care. Headquartered north of Chicago in Lake Forest,
Illinois. Hospira has approximately 16,000 employees worldwide and generated
approximately $4.1 billion in net sales in 2012.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Dr. Liisa Hurme, Senior Vice President, Proprietary Products, Orion Corporation
tel. +358 50 966 2874
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1737025]
Unternehmensinformation / Kurzprofil:
Datum: 21.10.2013 - 19:10 Uhr
Sprache: Deutsch
News-ID 307725
Anzahl Zeichen: 3435
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 160 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Orion and Hospira have signed a license agreement to continue the collaboration with Precedex®"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
